ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jan 11, 2023 16:00 JST
Source:
Avance Clinical
Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program
SAN FRANCISCO, CA, Jan 11, 2023 - (ACN Newswire) - More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program which delivers streamlined clinical development from early phase in Australia expanding to sites in North America for later phases. All with the one CRO and dedicated teams across both regions.
Avance Clinical made the announcement at Biotech Showcase 2023 where the team is taking meetings via PartnershipOne. "Given this successful early adoption of GlobalReady we are expecting more than half of our biotech clients to join the program within the next six months," said Avance Clinical CEO Yvonne Lungershausen.
GlobalReady biotech clients are primarily biotechs from the US and Asia, with an increasing number expected from Europe over the next few months. Avance Clinical is the leading Australian-based biotech CRO with US operations, which has been recognized by Frost & Sullivan for the past 3 years with the prestigious CRO Leadership Award.
Yvonne Lungershausen said: "These biotech clients are already benefiting from our expansion into North America and GlobalReady. The GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA-accepted data. GlobalReady gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximize their rebate potential. We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities."
This seamless GlobalReady journey is designed for success whereby biotechs can:
- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)
- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)
- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions
- Harness significant speed and cost advantages
- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities
"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biotech clients need for clinical success," commented Yvonne Lungershausen.
According to Frost & Sullivan as part of the independent analyst review of the company for the CRO Award: "Avance Clinical remains a trusted partner, earning a reputation for delivering the overall best in the CRO industry. With its strong overall performance, Avance Clinical earns Frost & Sullivan's 2022 Asia-Pacific Customer Value Leadership Award in the contract research organization industry."
Find out more:
- Learn about the Australian Advantage here
https://www.avancecro.com/the-australian-advantage/
- Learn about the GlobalReady model here
https://www.avancecro.com/avance-clinical-north-america-operations/
- Learn more about the benefits of running your next study with Avance Clinical at:
enquiries@avancecro.com
About Avance Clinical
Avance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.
https://www.avancecro.com/
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.
Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.
Media Contact:
Avance Clinical
Kate Thompson
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Delica Mini Wins 2023-2024 Japan Car of the Year Design Award
Dec 08, 2023 21:07 JST
Space Compass, NTT DOCOMO, NTT and SKY Perfect JSAT to Develop Direct-to-Device Service via Space-based Non-terrestrial Network
Dec 08, 2023 17:34 JST
MHI and ADNOC Sign Agreement to Explore Low Carbon Collaboration Opportunities to Build Blue NH3 and Blue H2 Value Chains
Dec 08, 2023 17:22 JST
MHI and Mitsubishi Logisnext Receive First Order from Kirin Group for an Automated Picking Solution
Dec 08, 2023 17:09 JST
Macau LRT Barra Extension Line Begins Commercial Operations on December 8
Dec 08, 2023 17:07 JST
Fujitsu and Palantir to strengthen strategic partnership to solve societal challenges and accelerate business transformation globally
Dec 08, 2023 16:28 JST
Honda to Begin Sales of Refreshed Odyssey in Japan
Dec 07, 2023 16:30 JST
Honda to Premiere New EV Series for Global Markets at CES 2024
Dec 07, 2023 13:00 JST
Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program
Dec 07, 2023 11:00 JST
Hitachi High-Tech Launches Dark Field Wafer Defect Inspection System DI4600 to Provide High Throughput and High-Precision Defect Detection on Patterned Wafers
Dec 06, 2023 17:38 JST
Fujitsu optimizes installation of EV charging infrastructure in India with Fujitsu Fleet Optimization solution trial
Dec 06, 2023 11:02 JST
Fujitsu Finland to provide comprehensive IT services to Kempower, provider of electric vehicle fast charging solutions
Dec 05, 2023 10:52 JST
DENSO Announces Organizational and Executive Changes
Dec 04, 2023 18:12 JST
All-New Triton Earns Top Rating in 2023 ASEAN NCAP
Dec 04, 2023 17:07 JST
Fujitsu and KDDI Research successfully implement large-capacity multiband wavelength multiplexing transmission with installed optical fiber
Dec 04, 2023 10:34 JST
GC Collaborates with MHI to explore the utilization of hydrogen, ammonia and CCS technology to develop a large-scale petrochemical plant to achieve Net Zero
Dec 01, 2023 17:22 JST
NEC named among IAM's 2023 Asia IP Elite
Dec 01, 2023 14:50 JST
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Nov 30, 2023 16:25 JST
Boosting Growth Investment to Power Mobility Company Transformation Toyota-DENSO Capital Ties Revised
Nov 30, 2023 16:17 JST
Olympus's Net-Zero Targets Approved by SBTi
Nov 30, 2023 11:00 JST
More Latest Release >>
Related Release
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies
May 25 2023 09:00 JST
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
April 18 2023 11:00 JST
Avance Clinical Wins International Health Award for Biotech CRO Services
September 28 2022 16:00 JST
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs
September 06 2022 13:00 JST
Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022
August 29 2022 18:00 JST
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC
April 19 2022 10:00 JST
Avance Clinical Announces New Office Opening in Melbourne
March 31 2022 15:00 JST
Avance Clinical Announces New Office Opening in Sydney
March 02 2022 15:00 JST
More Press release >>